PL2049562T3 - Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak - Google Patents

Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak

Info

Publication number
PL2049562T3
PL2049562T3 PL07786192T PL07786192T PL2049562T3 PL 2049562 T3 PL2049562 T3 PL 2049562T3 PL 07786192 T PL07786192 T PL 07786192T PL 07786192 T PL07786192 T PL 07786192T PL 2049562 T3 PL2049562 T3 PL 2049562T3
Authority
PL
Poland
Prior art keywords
alkylated
natural
optionally
substituted
amino acid
Prior art date
Application number
PL07786192T
Other languages
English (en)
Inventor
Maria Vincenza Carriero
Rosa Mario De
Vincenzo Pavone
Original Assignee
Kaleyde Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaleyde Pharmaceuticals Ag filed Critical Kaleyde Pharmaceuticals Ag
Publication of PL2049562T3 publication Critical patent/PL2049562T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PL07786192T 2006-08-09 2007-07-19 Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak PL2049562T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001607A ITMI20061607A1 (it) 2006-08-09 2006-08-09 Peptidi con attivita farmacologica
EP07786192A EP2049562B1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
PCT/EP2007/006424 WO2008017372A1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer

Publications (1)

Publication Number Publication Date
PL2049562T3 true PL2049562T3 (pl) 2013-07-31

Family

ID=38776401

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07786192T PL2049562T3 (pl) 2006-08-09 2007-07-19 Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak
PL10156101T PL2213680T3 (pl) 2006-08-09 2007-07-19 Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10156101T PL2213680T3 (pl) 2006-08-09 2007-07-19 Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak

Country Status (23)

Country Link
US (1) US8354374B2 (pl)
EP (3) EP2213680B1 (pl)
JP (1) JP5384342B2 (pl)
KR (1) KR101464576B1 (pl)
CN (1) CN101501060B (pl)
AT (1) ATE544775T1 (pl)
AU (1) AU2007283150B2 (pl)
BR (1) BRPI0715407A2 (pl)
CA (1) CA2660183C (pl)
CY (2) CY1113941T1 (pl)
DK (2) DK2213680T3 (pl)
ES (2) ES2404052T3 (pl)
HK (1) HK1136304A1 (pl)
HR (1) HRP20130331T1 (pl)
IL (1) IL196929A (pl)
IT (1) ITMI20061607A1 (pl)
ME (1) ME02425B (pl)
MX (1) MX2009001452A (pl)
PL (2) PL2049562T3 (pl)
PT (2) PT2213680E (pl)
RS (1) RS52786B (pl)
SI (2) SI2213680T1 (pl)
WO (1) WO2008017372A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121130A1 (es) 2009-07-13 2012-08-30 Zealand Pharma As Analogos de glucagon acilados
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA034322B1 (ru) 2013-10-17 2020-01-28 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TWI670281B (zh) 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
MX2017005457A (es) 2014-10-29 2017-07-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
ITUB20169937A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
EP3231811A1 (en) 2016-04-11 2017-10-18 Istituto Nazionale Tumori Irccs "Fondazione G. Pascale" Retro-inverso peptide inhibitors of cell migration, extracellular matrix and endothelial invasion by tumor cells
US20190145962A1 (en) * 2016-04-14 2019-05-16 Tao Health Life Pharma Co., Ltd. Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
KR20210068093A (ko) * 2018-09-28 2021-06-08 넛크래커 테라퓨틱스 인코포레이티드 핵산 전달을 위한 지질화 양이온성 펩타이드 화합물을 포함하는 지질 나노입자 제형
IT202200007754A1 (it) 2022-04-19 2023-10-19 Iridea S R L Nuovi composti con attivita’ farmacologica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8202788A1 (es) * 1981-04-23 1982-02-16 Jorba Puigsubira Jose Ma Un procedimiento para la preparacion de oligopeptidos lisi- na-triptofano y de sus derivados y sales fisiologicamente aprovechables
CA2094785A1 (en) * 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6388054B1 (en) * 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
DK174549B1 (da) * 2000-02-01 2003-05-26 Raaco Internat A S Indretning til optagelse og fastholdelse af værktøjer
JP2003528317A (ja) * 2000-03-23 2003-09-24 ノバルティス アクチエンゲゼルシャフト 肥満細胞／好塩基球活性化阻害剤の同定
AU2001244609A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Novel protein, dna thereof and process for producing the same
AU2001292658A1 (en) * 2000-09-13 2002-03-26 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
DE60219888T2 (de) * 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002085399A1 (en) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
EP1414849B1 (en) * 2002-01-29 2009-04-29 Posco Immune-modulating peptide
US7267942B2 (en) * 2003-03-24 2007-09-11 The University Of Hong Kong Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
CA2571420A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8143228B2 (en) * 2004-07-12 2012-03-27 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
ES2469676T3 (es) * 2006-05-25 2014-06-18 Bayer Intellectual Property Gmbh Complejos moleculares dim�ricos

Also Published As

Publication number Publication date
WO2008017372A1 (en) 2008-02-14
CY1114014T1 (el) 2016-07-27
RS52786B (en) 2013-10-31
CA2660183A1 (en) 2008-02-14
EP2213680A1 (en) 2010-08-04
DK2213680T3 (da) 2013-05-06
PL2213680T3 (pl) 2013-08-30
HK1136304A1 (en) 2010-06-25
JP5384342B2 (ja) 2014-01-08
EP2230245B1 (en) 2012-02-08
BRPI0715407A2 (pt) 2013-07-02
DK2049562T3 (da) 2013-04-15
ITMI20061607A1 (it) 2008-02-10
KR101464576B1 (ko) 2014-12-04
CY1113941T1 (el) 2016-07-27
MX2009001452A (es) 2009-04-08
SI2049562T1 (sl) 2013-06-28
JP2010500298A (ja) 2010-01-07
EP2230245A1 (en) 2010-09-22
PT2049562E (pt) 2013-04-24
KR20090051041A (ko) 2009-05-20
AU2007283150B2 (en) 2012-11-29
PT2213680E (pt) 2013-05-10
SI2213680T1 (sl) 2013-06-28
HRP20130331T1 (hr) 2013-05-31
US8354374B2 (en) 2013-01-15
ES2406090T3 (es) 2013-06-05
IL196929A0 (en) 2009-11-18
AU2007283150A1 (en) 2008-02-14
ME02425B (me) 2016-09-20
CN101501060A (zh) 2009-08-05
CN101501060B (zh) 2012-11-07
EP2049562A1 (en) 2009-04-22
EP2213680B1 (en) 2013-03-20
US20110230397A1 (en) 2011-09-22
IL196929A (en) 2016-02-29
EP2049562B1 (en) 2013-02-27
CA2660183C (en) 2016-09-27
ES2404052T3 (es) 2013-05-23
ATE544775T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
HRP20130331T1 (hr) Peptidi koji imaju farmakološku aktivnost za lijeäśenje poremeä†aja povezanih s migracijom promijenjenih stanica kao što su stanice karcinoma
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
TW200833365A (en) Neuronal exocytosis inhibiting peptides
IL180727A (en) Antifungal peptides containing motif including arginine and / or lysine
WO2012164488A3 (en) New cosmetic or dermopharmaceutical topical use of a mixture of a ghk tripeptide and gqpr tetrapeptide
SG191069A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
ECSP13013115A (es) Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales
MX2020004912A (es) Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar.
RU2010107788A (ru) Аналоги инсулина с ацильной и алкиленгликолевой группировкой
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
NZ599791A (en) Therapeutic peptides
MY143765A (en) Neuropeptides for aquatic organisms culture
GB0524884D0 (en) Improvements in or relating to organic compounds
DE3784215D1 (de) Neue cystinverbindungen, ihre herstellung und verwendung.
MX2023005771A (es) Tetrapeptido y composiciones que comprenden tetrapeptidos.
ES447686A1 (es) Procedimiento para la preparacion de tripeptidos derivados de la l-prolina.
ECSP003720A (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
CU22988A3 (es) Amidas de ácidos fenilciclohexanocarboxílicos sustituidas con efecto inhibidor de la captación de adenosina
CY1117399T1 (el) Συνθεσεις και μεθοδοι για προληψη και θεραπεια νευροεκφυλιστικων ασθενειων
ECSP992914A (es) Procedimiento para la preparacion de acidos hidroxamicos
DE602007009797D1 (de) Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon